Archived Press Releases
May 2, 2000
Initiation of Clinical Trials of Onyvax Colorectal Cancer Vaccines
May 2, 2000. Two clinical trials of vaccines for treating colorectal
cancer have been initiated using vaccines produced by Onyvax Limited
(London, UK; www.onyvax.com).
The first trial, conducted by Dr Fiona Lofts, Consultant Oncologist
at St. George's Hospital, London, will recruit 45 patients with
metastatic disease. These patients will be treated with a cell-based
vaccine developed by Onyvax and with an antibody-based vaccine licensed
from the Cancer Research Campaign. Patient recruitment information
is available on the Colorectal Cancer Vaccine Trial Helpline: +44
(0)20 8682 9131
The second trial, conducted by Mr Mukul Dube at the Queen's Medical
Centre, Nottingham, will recruit a further 45 patients scheduled
for primary surgery to treat colorectal cancer and who will be treated
with the antibody-based vaccine.
Results from both of these trials are likely to be available in
around 18 months.
Professor Angus Dalgleish, Research Director said: "I am excited
about the prospects for vaccines to treat colorectal cancer. Clinical
experience to date with our prostate cancer vaccine has shown an
excellent safety and side-effect profile together with potent immune
responses induced by the vaccine. These new trials are assessing
two vaccines and we believe they may pave the way toward safe and
effective treatments for colorectal cancer patients."
Onyvax is a private company focussed on the development of therapies
that harness the power of the immune system in the fight against
cancer. It is believed that such an approach will benefit from the
power and selectivity of the immune system whilst offering an excellent
side-effect profile. To this end, Onyvax is developing vaccines
targeted to specific cancers.